Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Erlotinib in lung cancer - molecular and clinical predictors of outcome.

The New England journal of medicine - 14 Jul 2005

Tsao Ming-Sound, Sakurada Akira, Cutz Jean-Claude, Zhu Chang-Qi, Kamel-Reid Suzanne, Squire Jeremy, Lorimer Ian, Zhang Tong, Liu Ni, Daneshmand Manijeh, Marrano Paula, da Cunha Santos Gilda, Lagarde Alain, Richardson Frank, Seymour Lesley, Whitehead Marlo, Ding Keyue, Pater Joseph, Shepherd Frances A

Abstract excerpt

BACKGROUND: A clinical trial that compared erlotinib with a placebo for non-small-cell lung cancer demonstrated a survival benefit for erlotinib. We used tumor-biopsy samples from participants in this trial to investigate whether responsiveness to erlotinib and its impact on survival were associa...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Analysis of Variance

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Erlotinib Hydrochloride

Share to Protein Kinase Inhibitors

Share to Quinazolines

Share to Survival Analysis

Source

Identifiers

PMID: 16014883
DOI: 10.1056/NEJMoa050736

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-16014883-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Erlotinib in lung cancer - molecular and clinical predictors of outcome.PMID 16014883Read ↗

Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.Semantic proximity Read ↗

Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors.Semantic proximity Read ↗

Biological and clinical implications of EGFR mutations in lung cancer.Semantic proximity Read ↗

Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive.Semantic proximity Read ↗

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.Semantic proximity Read ↗

Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients.Semantic proximity Read ↗

A Prospective Observational Study Evaluating the Correlation of c-MET Expression and EGFR Gene Mutation with Response to Erlotinib as Second-Line Treatment for Patients with Advanced/Metastatic Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

EGFR inhibitors: what have we learned from the treatment of lung cancer?Semantic proximity Read ↗

A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer.Semantic proximity Read ↗

Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer.Semantic proximity Read ↗

The importance of molecular profiling in predicting response to epidermal growth factor receptor family inhibitors in non-small-cell lung cancer: focus on clinical trial results.Semantic proximity Read ↗

Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.